SCHEMBL3256609

SCHEMBL3256609

CCN(CC)C(=O)Cc1cnc(NS(=O)(=O)c2ccc(-c3ccccc3)cc2)s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
ALOX12 P18054 1/20 0.42
ALDH1A1 P00352 4/20 0.42
CYP2C9 P11712 2/20 0.42
TSHR P16473 1/20 0.42
CCNE1 P24864 2/20 0.42
CDK2 P24941 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
CCNE2 O96020 1/20 0.42
LIMK1 P53667 1/20 0.41
LIMK2 P53671 1/20 0.41
KMO O15229 1/20 0.41
CDK5 Q00535 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CYP2C19 P33261 1/20 0.41
GAA P10253 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ATM Q13315 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5964659 0.93 AKT1 (0.45) MEN1KMT2ACCNE1CDK2LIMK1
SCHEMBL3256780 0.91 ALOX12 (0.42) MEN1KMT2AALOX12ALDH1A1CYP2C9
SCHEMBL3254141 0.87 ALOX12 (0.44) MEN1KMT2AALOX12ALDH1A1CYP2C9
SCHEMBL3251115 0.86 ALOX12 (0.44) MEN1KMT2AALOX12ALDH1A1CYP2C9
SCHEMBL3252170 0.85 MMP1 (0.48) MEN1KMT2AALOX12TSHRCCNE1
SCHEMBL3251192 0.85 AKT1 (0.48) ALDH1A1SMN1; SMN2
SCHEMBL5832093 0.82 ATM (0.58) MEN1KMT2AALOX12ALDH1A1HSD17B10
SCHEMBL5831222 0.80 USP36 (0.46) MEN1KMT2AALDH1A1CYP2C9NPC1
SCHEMBL3621762 0.79 ALDH1A1 (0.64) MEN1KMT2AALDH1A1CYP2C9CYP2C19
SCHEMBL3255956 0.78 ALOX12 (0.43) MEN1KMT2AALOX12TSHRCCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1461325-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-05-26 EP claimed
US-7671051-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2010-03-02 US claimed
US-20050250776-A1 Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 BIOVITRUM AB 2005-11-10 US claimed
WO-2004112782-A1 NEW USE V BIOVITRUM AB (SE) 2004-12-29 WO claimed
US-20030130318-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US claimed
EP-1461325-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-05-26 EP disclosed
US-7671051-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2010-03-02 US disclosed
US-7094792-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-08-22 US disclosed
US-20050250776-A1 Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 BIOVITRUM AB 2005-11-10 US disclosed
US-20030130318-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250776-A1 Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 HSD11B1, HSD17B1, HSD17B11 MEN1 808/4885KMT2A 3602/4885ALOX12 535/4885
US-20030130318-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 MEN1 770/4885KMT2A 3247/4885ALOX12 388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.